Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03314974 · ClinicalTrials.gov registry record · Phase 2
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
A Phase 2 study of Lymphoma and Acute Myeloid Leukemia, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT03314974 is a Phase 2 study of Lymphoma and Acute Myeloid Leukemia that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 300 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03314974, a Phase 2 study of Lymphoma and Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).
Conditions Studied
Interventions
- BIOLOGICAL HSCT with TBI Regimen
- BIOLOGICAL HSCT with Non-TBI Regimen
Study Locations (1)
Minnesota
- Masonic Cancer Center at University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2027-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03314974
The ClinicalTrials.gov registry entry for NCT03314974 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (38% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which HSCT with TBI Regimen is the first listed.
NCT03314974 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03314974 about?
NCT03314974 is a clinical study titled "Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders". This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD...
What is the current status of trial NCT03314974?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2018-03-30. Estimated completion is 2027-06-10.
What conditions does trial NCT03314974 study?
This clinical trial studies the following conditions: Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelofibrosis, Acute Leukemia.
What interventions are being tested in trial NCT03314974?
The interventions under investigation include: HSCT with TBI Regimen (BIOLOGICAL), HSCT with Non-TBI Regimen (BIOLOGICAL).
Who is sponsoring clinical trial NCT03314974?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03314974 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
-
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.